Transcatheter aortic valve replacement in patients with systolic heart failure and moderate aortic stenosis shows limited benefits
Meeting Announcement
Updates every hour. Last Updated: 29-Apr-2025 10:10 ET (29-Apr-2025 14:10 GMT/UTC)
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
Findings were reported today at TCT 2024, the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine. The results were also published simultaneously in the Journal of the American College of Cardiology.
The EVOLVED trial found that early aortic valve intervention in patients with asymptomatic severe aortic stenosis (AS) and mid-wall myocardial fibrosis on magnetic resonance imaging did not reduce the incidence of the composite primary endpoint of all-cause death or unplanned aortic stenosis hospitalization compared with guideline-directed conservative management.
Findings were reported today at TCT 2024, the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine. The results were also published simultaneously in the Journal of the American Medical Association
The first powered randomized trial examining early intervention with transcatheter aortic valve replacement (TAVR) in patients with asymptomatic, severe aortic stenosis (AS) found this strategy to be both a safe and effective alternative to clinical surveillance (CS).
Findings were reported today at TCT 2024, the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine. Results were also published simultaneously in the New England Journal of Medicine.
A survey of patients receiving gender affirming care shows that commercial insurance pays for most of their treatments, they receive less care in the South than other parts of the U.S. and they deal with disproportionate levels of housing insecurity and trauma compared to others, according to a new study by researchers at the Colorado School of Public Health and the University of Colorado Anschutz Medical Campus.
The study, using data provided by Kythera Labs, a healthcare clearinghouse, examined millions of insurance claims by patients undergoing gender affirming care (GA) and those not. It also looked at social determinants of healthcare (SDOH), non-medical factors which affect a person’s quality of life.
The study was published today in the Journal of General Internal Medicine.
It showed that commercial insurance covered 72.8% of GA claims followed by Medicaid at 17.2 %, other insurance at 6.6% and Medicare at 3.5%. GA patients incurred more claims across all insurance and age groups, about 87% more overall.
Results from the large-scale randomized ECLIPSE trial found that a lesion preparation strategy of routine orbital atherectomy had similar outcomes compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in severely calcified coronary arteries.
Findings were reported today at TCT 2024, the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.
First-of-its kind work led by Mount Sinai researcher supports reserving this technique for extreme cases